Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. trimmed its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 22.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,464 shares of the life sciences company's stock after selling 21,053 shares during the period. Assenagon Asset Management S.A. owned about 0.09% of Integra LifeSciences worth $1,621,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Sachem Head Capital Management LP bought a new position in shares of Integra LifeSciences during the third quarter valued at approximately $44,153,000. Dimensional Fund Advisors LP boosted its position in Integra LifeSciences by 0.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company's stock valued at $52,014,000 after acquiring an additional 12,766 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Integra LifeSciences by 15.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company's stock valued at $17,158,000 after acquiring an additional 125,620 shares during the period. D. E. Shaw & Co. Inc. raised its position in shares of Integra LifeSciences by 64.6% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company's stock worth $24,925,000 after acquiring an additional 335,557 shares in the last quarter. Finally, Glenmede Trust Co. NA lifted its stake in shares of Integra LifeSciences by 125.9% during the 3rd quarter. Glenmede Trust Co. NA now owns 727,781 shares of the life sciences company's stock worth $13,224,000 after purchasing an additional 405,624 shares during the last quarter. Hedge funds and other institutional investors own 84.78% of the company's stock.

Integra LifeSciences Stock Performance

Integra LifeSciences stock traded up $0.45 during trading hours on Friday, hitting $26.05. 551,282 shares of the stock traded hands, compared to its average volume of 583,305. Integra LifeSciences Holdings Co. has a 1 year low of $16.81 and a 1 year high of $45.42. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of -289.41, a P/E/G ratio of 0.83 and a beta of 1.16. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The firm's 50 day moving average price is $23.32 and its 200-day moving average price is $22.37.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.02. The company had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. Integra LifeSciences's quarterly revenue was down .4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.76 EPS. As a group, equities analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the sale, the executive vice president now owns 56,182 shares in the company, valued at approximately $1,357,357.12. This represents a 2.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 3.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Truist Financial reduced their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating for the company in a report on Monday, October 14th. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They set an "underweight" rating and a $20.00 price objective for the company. BTIG Research upgraded shares of Integra LifeSciences from a "sell" rating to a "neutral" rating in a research note on Monday, October 7th. Bank of America reduced their price target on Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating on the stock in a research report on Monday, October 7th. Finally, Citigroup raised their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a research report on Tuesday, November 5th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, Integra LifeSciences has an average rating of "Hold" and an average price target of $23.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.